[1] 中华医学会肝病学分会和传染病与寄生虫病学分会. 丙型肝炎防治指南. 中华肝脏病杂志,2004,12 （4）:194-198.
[2] Armstrong GL,Wasley A,Simard EP,et al.The prevalence of hepatitis C virus infection in the United States,1999 through 2002. Ann Intern Med,2006,（144）:705-714.
[3] Ghany MG,Strader DB,Thomas DL,et al.Diagnosis,management,and treatment of hepatitis C:an update.Hepatology,2009,49（4）:1335-1374.
[4] Seeff LB.Natural history of chronic hepatitis C.Hepatology,2002,36（5 Suppl 1）:S35-S46.
[5] 亚太地区肝病研究协会丙型肝炎协助组.亚太区肝病年会丙型肝炎诊治专家共识.中华实验和临床感染病杂志,2007,1（1）: 88-94.
[6] D'souza R,Glynn MJ,Ushiro-Lumb I,et al.Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol,2005,3（9）:910-917.
[7] Kobayashi S,Takeda T,Enomoto M,et al.Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy:a multicenter,retrospective cohort study of 1124 patients. Liver Int,2007,27（2）:186-191.
[8] George SL,Bacon BR,Brunt EM,et al.Clinical,virologic,histologic,and biochemical outcomes after successful HCV therapy: a 5 year follow up of 150 patients.Hepatology,2009,49（3）:729-738.
[9] Ge D,Fellay J,Thompson AJ,et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.Nature,2009,461（7262）:399-401.
[10] Rauch A,Kutalik Z,Descombes P,et al.Genetic variation inIL28B is associated with chronic hepatitis C and treatment failure:a genome-wide association study. Gastroenterology,2010,138（4）:1338-1345.
[11] Thomas DL,Thio CL,Martin MP,et al.Genetic variation inIL28B and spontaneous clearance of hepatitis C virus.Nature,2009,461（7265）:798-801.
[12] Suppiah V,Moldovan M,Ahlenstiel G,et al.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.Nat Genet,2009,41:1100-1104.
[13] Kawaoka T,Hayes CN,Ohishi W,et al.Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.J Hepatol,2011,54（3）:408-414.
[14] Kurosaki M,Tanaka Y,Nishida N,et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.J Hepatol,2011,54（3）:439-448.
[15] Afdhal NH,Mchutchison JG,Zeuzem S,et al. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology,2011,53（1）:336-345.
[16] Abstract of the American Association for the Study of Liver Diseases:62nd annual meeting. November 4-8,2011. San Francisco,California,USA. Hepatology,2011,54 Suppl:360A-1513A.
[17] Pockros PJ. New direct-acting antivirals in the development for hepatitis C virus infection.Therap Adv Gastroenterol,2010,3（3）:191-202.
[18] Jacobson IM,McHutchison JG,Dusheiko GM,et al. Telaprevir in combination with peg-interferon and ribavirin in genotype 1 HCV treatment-naive patients:final results of Phase 3 ADVANCE study. Hepatology,2010,52:427A.
[19] Sherman KE,Flamm SL,Afdhal NH,et al. Telaprevir in combination with peginterferon alfa2b and ribavirin for 24 or 48 weeks in treatment naive genotype 1 HCV patients who achieved an extended rapid viral response:final results of Phase 3 ILLUMINATE study. Hepatology,2010,52:401A.
[20] Zeuzem S,Andreone P,Pol S,et al. Realize trial results: Telaplaprevir based regimen for genotype 1 hepatitis C virus infection in patients with prior null response,partial response or relapse to peginterferon /ribavirin. J Hepatol,2011,54（Suppl）:S3A.
[21] Bacon BR,Gordon SC,Lawitz E,et al. HCV RESPOND-2 final results:high sustained virologic response among genotype1 previous nonresponders and relapsers to peginterferon /ribavirin when retreated with boceprevir plus pegintron /ribavirin. Hepatology,2010,52:430A.
[22] Poordad F,Mccone J,Bacon BR,et al. Boceprevir（BOC）combined with peginterferon alfa-2b/ribavirin（P/R） for treatment-naive patients with hepatitis C（HCV） genotype 1:SPRINT-2 final results. Hepatology,2010,52:402A.
[23] Bruno S,Vierling JM,Esteban R,et al. Boceprevir in addition to atandasd of care enhanced SVR in hepatitis C virus（HCV） genotype-1 with advanced fibrosis /cirrhosis:Subgroup analysis of SPRINT-2 and RESPOND-2 studies. J Hepatol,2011,54（Suppl）:S4A.
[24] Ghany MG,Nelson DR,Strader DB,et al. An update on treatment of genotype 1 chronic hepatitis C virus infection:2011 practice guideline by the American Association for the Study of Liver Diseases.Hepatology,2011,54（4）:1433-1444.
[25] Lok A,Gardiner D,Lawitz E,et a1. Combination therapy with BMS 790052 and BMS4550032 alone or with peglFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders. Hepatology,2010,52 （Suppl 1）：877A. |
